CoChat

Precancer Atlas to Drive Precision Prevention Trials

Open access
Spira, Avrum, Yurgelun, Matthew B., Alexandrov, Ludmil, Rao, Anjana, Bejar, Rafael, Polyak, Kornelia, Giannakis, Marios, Shilatifard, Ali, Finn, Olivera J., Dhodapkar, Madhav, Kay, Neil E., Braggio, Esteban, Vilar, Eduardo, Mazzilli, Sarah A., Rebbeck, Timothy R., Garber, Judy E., Velculescu, Victor E., Disis, Mary L., Wallace, Douglas C., Lippman, Scott M. · 2017 · Cancer Research
Cited by 129

The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.

Abstract

Cancer development is a complex process driven by inherited and acquired molecular and cellular alterations. Prevention is the holy grail of cancer elimination, but making this a reality will take a fundamental rethinking and deep understanding of premalignant biology. In this Perspective, we propose a national concerted effort to create a Precancer Atlas (PCA), integrating multi-omics and immunity – basic tenets of the neoplastic process. The biology of neoplasia caused by germline mutations has led to paradigm-changing precision prevention efforts, including: tumor testing for mismatch repair (MMR) deficiency in Lynch syndrome establishing a new paradigm, combinatorial chemoprevention efficacy in familial adenomatous polyposis (FAP), signal of benefit from imaging-based early detection research in high-germline risk for pancreatic neoplasia, elucidating early ontogeny in BRCA1-mutation carriers leading to an international breast cancer prevention trial, and insights into the intricate germline-somatic-immunity interaction landscape. Emerging genetic and pharmacologic (metformin) disruption of mitochondrial (mt) respiration increased autophagy to prevent cancer in a Li-Fraumeni mouse model (biology reproduced in clinical pilot) and revealed profound influences of subtle changes in mt DNA background variation on obesity, aging, and cancer risk. The elaborate communication between the immune system and neoplasia includes an increasingly complex cellular microenvironment and dynamic interactions between host genetics, environmental factors, and microbes in shaping the immune response. Cancer vaccines are in early murine and clinical precancer studies, building on the recent successes of immunotherapy and HPV vaccine immune prevention. Molecular monitoring in Barrett's esophagus to avoid overdiagnosis/treatment highlights an important PCA theme. Next generation sequencing (NGS) discovered age-related clonal hematopoiesis of indeterminate potential (CHIP). Ultra-deep NGS reports over the past year have redefined the premalignant landscape remarkably identifying tiny clones in the blood of up to 95% of women in their 50s, suggesting that potentially premalignant clones are ubiquitous. Similar data from eyelid skin and peritoneal and uterine lavage fluid provide unprecedented opportunities to dissect the earliest phases of stem/progenitor clonal (and microenvironment) evolution/diversity with new single-cell and liquid biopsy technologies. Cancer mutational signatures reflect exogenous or endogenous processes imprinted over time in precursors. Accelerating the prevention of cancer will require a large-scale, longitudinal effort, leveraging diverse disciplines (from genetics, biochemistry, and immunology to mathematics, computational biology, and engineering), initiatives, technologies, and models in developing an integrated multi-omics and immunity PCA – an immense national resource to interrogate, target, and intercept events that drive oncogenesis. Cancer Res; 77(7); 1510–41. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-16-2346

Cites

101 of 101 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 101 references

Cited by

See all 129

Metadata

Authors
Spira, A., Yurgelun, M. B., Alexandrov, L., Rao, A., Bejar, R., Polyak, K., Giannakis, M., Shilatifard, A., Finn, O. J., Dhodapkar, M., Kay, N. E., Braggio, E., Vilar, E., Mazzilli, S. A., Rebbeck, T. R., Garber, J. E., Velculescu, V. E., Disis, M. L., Wallace, D. C., & Lippman, S. M.
Venue
Cancer Research
Published
2017-04-01
Volume
77
Issue
7
Pages
1510-1541
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2604434270
Cited by
129
References
101
FWCI
4.99
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Precancer Atlas to Drive Precision Prevention Trials. https://app.cochat.ai/papers/10.1158/0008-5472.can-16-2346
The paper
Spira, A., Yurgelun, M. B., Alexandrov, L., Rao, A., Bejar, R., Polyak, K., Giannakis, M., Shilatifard, A., Finn, O. J., Dhodapkar, M., Kay, N. E., Braggio, E., Vilar, E., Mazzilli, S. A., Rebbeck, T. R., Garber, J. E., Velculescu, V. E., Disis, M. L., Wallace, D. C., & Lippman, S. M. (2017). Precancer Atlas to Drive Precision Prevention Trials. Cancer Research. https://doi.org/10.1158/0008-5472.can-16-2346

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.